Incidence, risk factors and outcomes of de novo malignancies post liver transplantation

Pavan Kedar Mukthinuthalapati, Raghavender Gotur, Marwan Ghabril

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Liver transplantation (LT) is associated with a 2 to 7 fold higher, age and gender adjusted, risk of de novo malignancy. The overall incidence of de novo malignancy post LT ranges from 2.2% to 26%, and 5 and 10 years incidence rates are estimated at 10% to 14.6% and 20% to 32%, respectively. The main risk factors for de novo malignancy include immunosuppression with impaired immunosurveillance, and a number of patient factors which include; age, latent oncogenic viral infections, tobacco and alcohol use history, and underlying liver disease. The most common cancers after LT are non-melanoma skin cancers, accounting for approximately 37% of de novo malignancies, with a noted increase in the ratio of squamous to basal cell cancers. While these types of skin cancer do not impact patient survival, post-transplant lymphoproliferative disorders and solid organ cancer, accounting for 25% and 48% of malignancies, are associated with increased mortality. Patients developing these types of cancer are diagnosed at more advanced stages, and their cancers behave more aggressively compared with the general population. Patients undergoing LT for primary sclerosing cholangitis (particularly with inflammatory bowel disease) and alcoholic liver disease have high rates of malignancies compared with patients undergoing LT for other indications. These populations are at particular risk for gastrointestinal and aerodigestive cancers respectively. Counseling smoking cessation, skin protection from sun exposure and routine clinical follow-up are the current approach in practice. There are no standardized surveillance protocol, but available data suggests that regimented surveillance strategies are needed and capable of yielding cancer diagnosis at earlier stages with better resulting survival. Evidence-based strategies are needed to guide optimal surveillance and safe minimization of immunosuppression.

Original languageEnglish (US)
Pages (from-to)533-544
Number of pages12
JournalWorld Journal of Hepatology
Volume8
Issue number12
DOIs
StatePublished - Apr 28 2016

Fingerprint

Liver Transplantation
Incidence
Neoplasms
Skin Neoplasms
Immunosuppression
Basal Cell Neoplasms
Immunologic Monitoring
Sclerosing Cholangitis
Alcoholic Liver Diseases
Gastrointestinal Neoplasms
Survival
Lymphoproliferative Disorders
Tobacco Use
Solar System
Virus Diseases
Smoking Cessation
Liver Neoplasms
Inflammatory Bowel Diseases
Early Detection of Cancer
Liver Diseases

Keywords

  • Immunosuppression
  • Liver transplant
  • Malignancy
  • Outcomes
  • Risk

ASJC Scopus subject areas

  • Hepatology

Cite this

Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. / Mukthinuthalapati, Pavan Kedar; Gotur, Raghavender; Ghabril, Marwan.

In: World Journal of Hepatology, Vol. 8, No. 12, 28.04.2016, p. 533-544.

Research output: Contribution to journalArticle

Mukthinuthalapati, Pavan Kedar ; Gotur, Raghavender ; Ghabril, Marwan. / Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. In: World Journal of Hepatology. 2016 ; Vol. 8, No. 12. pp. 533-544.
@article{33017d1317c648258cf87f94b4487585,
title = "Incidence, risk factors and outcomes of de novo malignancies post liver transplantation",
abstract = "Liver transplantation (LT) is associated with a 2 to 7 fold higher, age and gender adjusted, risk of de novo malignancy. The overall incidence of de novo malignancy post LT ranges from 2.2{\%} to 26{\%}, and 5 and 10 years incidence rates are estimated at 10{\%} to 14.6{\%} and 20{\%} to 32{\%}, respectively. The main risk factors for de novo malignancy include immunosuppression with impaired immunosurveillance, and a number of patient factors which include; age, latent oncogenic viral infections, tobacco and alcohol use history, and underlying liver disease. The most common cancers after LT are non-melanoma skin cancers, accounting for approximately 37{\%} of de novo malignancies, with a noted increase in the ratio of squamous to basal cell cancers. While these types of skin cancer do not impact patient survival, post-transplant lymphoproliferative disorders and solid organ cancer, accounting for 25{\%} and 48{\%} of malignancies, are associated with increased mortality. Patients developing these types of cancer are diagnosed at more advanced stages, and their cancers behave more aggressively compared with the general population. Patients undergoing LT for primary sclerosing cholangitis (particularly with inflammatory bowel disease) and alcoholic liver disease have high rates of malignancies compared with patients undergoing LT for other indications. These populations are at particular risk for gastrointestinal and aerodigestive cancers respectively. Counseling smoking cessation, skin protection from sun exposure and routine clinical follow-up are the current approach in practice. There are no standardized surveillance protocol, but available data suggests that regimented surveillance strategies are needed and capable of yielding cancer diagnosis at earlier stages with better resulting survival. Evidence-based strategies are needed to guide optimal surveillance and safe minimization of immunosuppression.",
keywords = "Immunosuppression, Liver transplant, Malignancy, Outcomes, Risk",
author = "Mukthinuthalapati, {Pavan Kedar} and Raghavender Gotur and Marwan Ghabril",
year = "2016",
month = "4",
day = "28",
doi = "10.4254/wjh.v8.i12.533",
language = "English (US)",
volume = "8",
pages = "533--544",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "12",

}

TY - JOUR

T1 - Incidence, risk factors and outcomes of de novo malignancies post liver transplantation

AU - Mukthinuthalapati, Pavan Kedar

AU - Gotur, Raghavender

AU - Ghabril, Marwan

PY - 2016/4/28

Y1 - 2016/4/28

N2 - Liver transplantation (LT) is associated with a 2 to 7 fold higher, age and gender adjusted, risk of de novo malignancy. The overall incidence of de novo malignancy post LT ranges from 2.2% to 26%, and 5 and 10 years incidence rates are estimated at 10% to 14.6% and 20% to 32%, respectively. The main risk factors for de novo malignancy include immunosuppression with impaired immunosurveillance, and a number of patient factors which include; age, latent oncogenic viral infections, tobacco and alcohol use history, and underlying liver disease. The most common cancers after LT are non-melanoma skin cancers, accounting for approximately 37% of de novo malignancies, with a noted increase in the ratio of squamous to basal cell cancers. While these types of skin cancer do not impact patient survival, post-transplant lymphoproliferative disorders and solid organ cancer, accounting for 25% and 48% of malignancies, are associated with increased mortality. Patients developing these types of cancer are diagnosed at more advanced stages, and their cancers behave more aggressively compared with the general population. Patients undergoing LT for primary sclerosing cholangitis (particularly with inflammatory bowel disease) and alcoholic liver disease have high rates of malignancies compared with patients undergoing LT for other indications. These populations are at particular risk for gastrointestinal and aerodigestive cancers respectively. Counseling smoking cessation, skin protection from sun exposure and routine clinical follow-up are the current approach in practice. There are no standardized surveillance protocol, but available data suggests that regimented surveillance strategies are needed and capable of yielding cancer diagnosis at earlier stages with better resulting survival. Evidence-based strategies are needed to guide optimal surveillance and safe minimization of immunosuppression.

AB - Liver transplantation (LT) is associated with a 2 to 7 fold higher, age and gender adjusted, risk of de novo malignancy. The overall incidence of de novo malignancy post LT ranges from 2.2% to 26%, and 5 and 10 years incidence rates are estimated at 10% to 14.6% and 20% to 32%, respectively. The main risk factors for de novo malignancy include immunosuppression with impaired immunosurveillance, and a number of patient factors which include; age, latent oncogenic viral infections, tobacco and alcohol use history, and underlying liver disease. The most common cancers after LT are non-melanoma skin cancers, accounting for approximately 37% of de novo malignancies, with a noted increase in the ratio of squamous to basal cell cancers. While these types of skin cancer do not impact patient survival, post-transplant lymphoproliferative disorders and solid organ cancer, accounting for 25% and 48% of malignancies, are associated with increased mortality. Patients developing these types of cancer are diagnosed at more advanced stages, and their cancers behave more aggressively compared with the general population. Patients undergoing LT for primary sclerosing cholangitis (particularly with inflammatory bowel disease) and alcoholic liver disease have high rates of malignancies compared with patients undergoing LT for other indications. These populations are at particular risk for gastrointestinal and aerodigestive cancers respectively. Counseling smoking cessation, skin protection from sun exposure and routine clinical follow-up are the current approach in practice. There are no standardized surveillance protocol, but available data suggests that regimented surveillance strategies are needed and capable of yielding cancer diagnosis at earlier stages with better resulting survival. Evidence-based strategies are needed to guide optimal surveillance and safe minimization of immunosuppression.

KW - Immunosuppression

KW - Liver transplant

KW - Malignancy

KW - Outcomes

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=85019058085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019058085&partnerID=8YFLogxK

U2 - 10.4254/wjh.v8.i12.533

DO - 10.4254/wjh.v8.i12.533

M3 - Article

AN - SCOPUS:85019058085

VL - 8

SP - 533

EP - 544

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 12

ER -